Bysumlog
Insulin lispro biosimilar developed by Gan & Lee Pharmaceuticals. Reference product Humalog.
About Bysumlog
Bysumlog is Gan & Lee's insulin lispro, approved in Europe in May 2026, the second insulin lispro biosimilar there and nine years after the first. It completes Gan & Lee's set of three European insulins with Ondibta and Dazparda.
Status by market
United States
Not listed by FDA.
European Union · Bysumlog
European Medicines Agency and European CommissionApprovedUnited Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Bysumlog holds an approval, these are the other insulin lispro biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| EMA | 1 | Sanofi (Insulin lispro Sanofi) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Gan & Lee Pharmaceuticals: Dazparda, Ondibta.
Chronology
- EMAMay 2026Authorised by the European Commission
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning insulin lispro biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant